The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net earnings | 697 | 1,815 | 188 | 941 |
| Depreciation | 188 | 203 | 192 | 186 |
| Amortization of intangible assets | 1,748 | 1,784 | 1,871 | 1,864 |
| Deferred income taxes | 137 | -385 | 193 | -272 |
| Change in fair value of contingent consideration liabilities | 2,387 | 1,406 | 776 | 2,795 |
| Payments of contingent consideration liabilities | 722 | 681 | 776 | 859 |
| Stock-based compensation | 444 | 157 | 209 | 179 |
| Acquired ipr&d and milestones | 744 | 1,265 | 2,828 | 2,190 |
| Non-cash litigation reserve adjustments, net of cash payments | 150 | 136 | -319 | -21 |
| Impairment of intangible assets | - | 0 | 847 | - |
| Other, net | 22 | 9 | 90 | -79 |
| Accounts receivable | -87 | -162 | 156 | 17 |
| Inventories | 184 | 25 | -2 | 56 |
| Prepaid expenses and other assets | 150 | 658 | -88 | -371 |
| Accounts payable and other liabilities | -1,594 | -598 | 1,730 | 515 |
| Income tax assets and liabilities, net | -81 | 646 | -411 | -1,375 |
| Cash flows from operating activities | 3,829 | 5,218 | 7,024 | 5,153 |
| Acquisitions of businesses, net of cash acquired | 0 | 0 | 0 | 0 |
| Other acquisitions and investments, net of cash acquired | 266 | 1,161 | 2,802 | 940 |
| Acquisitions of property and equipment | 265 | 329 | 381 | 269 |
| Purchases of investment securities | - | 6 | 7 | 12 |
| Sales and maturities of investment securities | - | 34 | 3 | 7 |
| Other, net | 43 | 1 | 77 | -33 |
| Cash flows from investing activities | -574 | -1,463 | -3,264 | -1,181 |
| Net change in commercial paper borrowings with original maturities of three months or less | -499 | -500 | -550 | -44 |
| Proceeds from short-term debt | - | 0 | 791 | 4,007 |
| Repayments of other short-term borrowings | 2,000 | 791 | 2,007 | 0 |
| Proceeds from issuance of long-term debt | 7,991 | 0 | 0 | 0 |
| Repayments of long-term debt | 0 | 8 | 9 | 3,754 |
| Debt issuance costs | - | 0 | 0 | 23 |
| Dividends paid | 3,086 | 2,911 | 2,911 | 2,910 |
| Purchases of treasury stock | 1,489 | 3 | 4 | 12 |
| Proceeds from the exercise of stock options | - | 48 | 63 | 5 |
| Payments of contingent consideration liabilities | - | 0 | - | - |
| Other, net | 2 | -1 | 37 | 1 |
| Cash flows from financing activities | 919 | -4,166 | -4,590 | -2,710 |
| Effect of exchange rate changes on cash and equivalents | -12 | 11 | -8 | 30 |
| Net change in cash and equivalents | 4,162 | -400 | -838 | 1,292 |
| Cash and equivalents, beginning of period | 5,229 | 5,629 | 6,467 | 5,175 |
| Cash and equivalents, end of period | 9,391 | 5,229 | 5,629 | 6,467 |
AbbVie Inc. (ABBV)
AbbVie Inc. (ABBV)